NANO Nanobiotix SA

Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference

Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference

PARIS and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Laurent Levy, co-founder of Nanobiotix and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on Wednesday, February 7, 2024, at 3:00 PM ET / 9:00 PM CET in New York, NY.

The fireside chat will be webcast live from the of the Investors section of the Company’s website. A replay of the webcast will be available following the event.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in, among other, Cambridge, Massachusetts (United States).

Nanobiotix is the owner of more than 20 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at or follow us on and .

Contacts

Nanobiotix 


Communications Department


Brandon Owens

VP, Communications

+1 (617) 852-4835







Investor Relations Department


Craig West

SVP, Investor Relations

+1 (617) 583-0211



 
Media Relations 


FR – Ulysse Communication

Pierre-Louis Germain

+ 33 (0) 6 64 79 97 51







Global – LifeSci Advisors

Kevin Gardner

+1 (617) 283-2856

 

 

Attachment



EN
31/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nanobiotix SA

 PRESS RELEASE

Information mensuelle relative au nombre total de droits de vote et d’...

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 16 mai 2024 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / NasdaqEuronext Compartiment : B Code ISIN : FR0011341205Nasdaq : NBTXBloomberg : NANO:FPReuters : NANO.PASite web : DateNombre total d’actions composant le capital socialNombre total de droits de voteTotal théorique1Total exerçable230 avril 202447 133 32848 903 29848 881 180 En applic...

 PRESS RELEASE

Voting Rights and Shares Capital of the Company

Voting Rights and Shares Capital of the Company In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, May 16, 2024 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: DateNumber of SharesOutstandingTotal number of voting rightsTotal voting rights,theoretical1Total voting rights,exercisable2April 30, 202447,133,32848,903,29848,881,180 According to the arti...

 PRESS RELEASE

NANOBIOTIX to Announce First Quarter Operational and Financial Update ...

NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024 Conference call and webcast scheduled on May 22, 2024, at 8:00 am EDT / 2:00 pm CEST PARIS and CAMBRIDGE, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that it will report its financial and operational results for the first quarter of 2024 on May 22, 2024, before the US and EU markets open. This release...

 PRESS RELEASE

NANOBIOTIX publiera ses résultats financiers et opérationnels du premi...

NANOBIOTIX publiera ses résultats financiers et opérationnels du premier trimestre 2024 le 22 mai 2024 Conférence téléphonique et diffusion en direct sur Internet le 22 mai 2024 à 14 h 00 CEST / 8 h 00 EDT PARIS et CAMBRIDGE, Mass., 15 mai 2024 (GLOBE NEWSWIRE) -- (Euronext : NANO –– NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des approches fondées sur la physique pour élargir les possibilités de traitement des patients atteints de cancer, annonce aujourd’hui qu’elle publiera, le 22 mai 2024, avant l’ouvertu...

 PRESS RELEASE

NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Pha...

NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer PARIS and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that the U.S. Food and Drug Administration (“US FDA”) issued a Study May Proceed Letter for a randomized Phase 2 study evaluating NBTXR3 for t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch